Streetbeat News

Price Targets

ABBV

Raymond James analyst Gary Nachman maintains an Outperform rating on AbbVie (NYSE:ABBV) and raises the price target from $181 to $189.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:24 pm

UTHR

Leerink Partners has initiated coverage on United Therapeutics (NASDAQ:UTHR) with an Outperform rating and set a price target of $330.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:15 pm

SN

Guggenheim analyst Steven Forbes initiates coverage on SharkNinja (NYSE:SN) with a Buy rating and a price target of $60.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:13 pm

ITW

Barclays analyst Julian Mitchell has maintained an Underweight rating on Illinois Tool Works (ITW) but raised the price target from $215 to $224.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:12 pm

SKYE

Piper Sandler analyst Edward Tenthoff has initiated coverage on Skye Bioscience (OTC:SKYE) with an Overweight rating and set a price target of $12. This move could indicate a positive outlook on SKYE's future performance.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:11 pm

GRAB

Barclays analyst Jiong Shao maintains an Overweight rating on Grab Holdings (NASDAQ:GRAB) but lowers the price target from $4.5 to $4.3.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:09 pm

SDHC

B of A Securities analyst Rafe Jadrosich initiates coverage on Smith Douglas Homes (NYSE:SDHC) with a Neutral rating and a price target of $28.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:09 pm

DOV

Barclays analyst Julian Mitchell has maintained an Equal-Weight rating on Dover (NYSE:DOV) and increased the price target from $150 to $163.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:02 pm

CHTR

Barclays analyst Kannan Venkateshwar maintains an Underweight rating on Charter Communications (CHTR) and lowers the price target from $325 to $280.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:01 pm

MAT

Mattel (NASDAQ:MAT) received mixed analyst ratings with a shift towards a more neutral stance over the last quarter. Four analysts provided ratings, with a consensus moving from bullish to predominantly indifferent. The average 12-month price target was adjusted to $20.25, down from $24.67, indicating a negative sentiment shift. Analysts from JP Morgan, Stifel, Morgan Stanley, and Roth MKM adjusted their price targets and ratings, reflecting concerns over Mattel's market position despite its strong financial indicators such as revenue growth, net margin, and ROE.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 12:01 pm